CLSDQ
Clearside Biomedical, Inc.
- PER (TTM)
- -
- PER (Forward)
- -0.06
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.03
- 시가총액
- 1.62M
- 배당수익률
- -
- 베타
- 1.86
- 1개월 수익률
- 3.33%
- 3개월 수익률
- -52.31%
- 6개월 수익률
- -92.38%
- 1년 수익률
- -97.56%
- 2년 수익률
- -
- 5일 평균거래량
- 2520
- 60일 평균거래량
- 21658
- 1년 평균거래량
- 157093
- 5d/60d 거래량 비율
- 0.12×
- 60d/1y 거래량 비율
- 0.14×
- 변동성(60일, 연환산)
- 305.77%
- BB 스퀴즈 스코어
- 0.76
- SMA50 비율
- 0.74
- SMA200 비율
- 0.13
- RSI (14)
- 46
- 20일 수렴도
- 0.13
- 52주 최고
- 13.50
- 52주 최저
- 0.21
- 고점 대비
- -97.70%
- 저점 대비
- 46.92%
펀더멘털 갱신: 2026-05-10T08:20:40+00:00 · 시세 갱신: 2026-05-10T06:18:31+00:00
회사 정보
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.